# MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

> **NCT05735717** · PHASE2 · RECRUITING · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 70 (estimated)

## Conditions studied

- Hematologic Malignancy
- Acute Leukemia
- Remission
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- AML
- TP53
- Intrachromosomal Amplification of Chromosome 21
- Cytogenetic Abnormality
- CNS Leukemia
- Minimal Residual Disease
- Myelodysplasia
- Juvenile Myelomonocytic Leukemia
- Somatic Mutation
- PTPN11 Gene Mutation
- N-RAS Gene Amplification
- Neurofibromatosis 1
- NF1 Mutation
- CBL Gene Mutation
- Monosomy 7
- Chromosome Abnormality
- Fetal Hemoglobin
- Lymphoblastic Lymphoma
- High Grade Non-Hodgkin's Lymphoma, Adult

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **DRUG:** Rituximab
- **DRUG:** Levetiracetam
- **BIOLOGICAL:** Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
- **DRUG:** Thymoglobulin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05735717
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-11
- **Primary completion:** 2027-11-30
- **Final completion:** 2030-11-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05735717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05735717, "MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05735717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*